Experienced Attorneys, Aggressive Representation


If You or Loved One Developed Cancer After Taking the Weight Loss Drug Belviq or Belviq XR, You could Be Owed Significant Monetary Compensation.

According to the Center for Drug Evaluation and Research, Belviq was approved for use in 2012, and Eisai, the drug manufacturer, was required to conduct long-term studies into cardiac safety. However, after reviewing the results of the five-year study, the federal watchdog agency pulled the drug from the market. The study indicated an overall increase for cancer and a particularly elevated risk for pancreatic, lung, and colorectal cancer with extended use.

FDA Finds Weight Loss Drug Could Increase Risk of Certain Cancers

According to the FDA, Belviq (lorcaserin) and Belviq XR were withdrawn from the market after clinical trials indicated the weight loss medication could increase the risk of certain cancers, including:

  • Pancreatic Cancer
  • Colorectal Cancer
  • Lung Cancer

Belviq Increased Risk of Cancer

The FDA made a public announcement regarding the safety of the medication, saying it requested a voluntary withdraw after the results of a 5-year clinical study indicated that several different types of cancer occurred more frequently in patients taking lorcaserin than in patients taking placebo.

Belviq is a popular weight-loss treatment for obesity. The drug helps patients feel full after eating less. However, the FDA recommends that patients stop taking Belviq and discuss alternative weight loss medications and programs with their doctors. The FDA acted after determining the risks of lorcaserin outweigh its medical benefits.

Time May Be Limited to File Your Claim, Don’t Delay

We are currently investigating cancer claims on behalf of patients and consumers who used Belivq or Belivq XR and developed certain types of cancer. But the countdown for how long you have to file a claim has already begun. Don’t delay, call Goldblatt + Singer today at (314) 888-1000.

Free Consultation

fields required *

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.